Trading in CELLINK’s shares commences today on Nasdaq Stockholm Main Market

CELLINK AB (publ) (“CELLINK” or the “Company”) (Nasdaq Stockholm: CLNK B) announces today the commencement of trading in the company’s shares on Nasdaq Stockholm Main Market.

“I would like to begin by thanking the entire CELLINK team, the board of directors, investors, and, above all, our customers for their continued trust and for their amazing work. This exciting journey started by four pioneers just four years ago and has now matured to a multinational company operating in six countries, with 200 brilliant employees, installations in more than 55 countries around the world, and is now listed on Nasdaq Stockholm Main Market. It is with tremendous pride, honor, and confidence that we look into the future entering into a new chapter for CELLINK, following the vision of changing the future of medicine as we know it.” Says Erik Gatenholm, CEO of CELLINK

CELLINK’s shares will continue to be traded under the same ticker (CLNK B) and ISIN code (SE0013647385). No new shares will be issued in connection with the listing. Shareholders of CELLINK do not need to take any action in connection with the listing on Nasdaq Stockholm Main Market.

For further information, please contact:

Erik Gatenholm, CEO

Phone (Sweden): +46 73 267 00 00

Phone (US): +1 (650) 515 5566

Email: [email protected]

Gusten Danielsson, CFO

Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (857) 332 2138

Email: [email protected]

The information was sent for publication, through the agency of the contact persons set out above, on April 20, 2020, at 08.30 CEST.

About CELLINK

CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.

Latest press releases
March 22, 2020RegulatoryUpdate regarding COVID-19
November 14, 2019Annual Report 2018/2019